Smitha Gubbi, MD
Family Medicine · Bridgewater, NJNPI 1275620650
Payments from drug & device makers
Across 428 payments — averaging $15.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$695
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$474
- Exact Sciences$334
- Johnson & Johnson$297
- Bayer$290
- plus $3K from 32 others
What the payments were for
- Food & beverage$6,635100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 83 | $1,120 |
| AstraZeneca | 47 | $695 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 38 | $474 |
| Exact Sciences | 12 | $334 |
| Johnson & Johnson(2 entities) | 22 | $297 |
| Bayer | 13 | $290 |
| Lilly USA, LLC | 18 | $282 |
| Otsuka America Pharmaceutical, Inc. | 16 | $276 |
| Boehringer Ingelheim | 18 | $268 |
| Pfizer | 16 | $248 |
| Astellas Pharma US Inc | 12 | $240 |
| AbbVie(2 entities) | 16 | $209 |
| Kowa Pharmaceuticals America, Inc. | 14 | $203 |
| GSK | 13 | $197 |
| Sanofi-aventis U.S. LLC | 11 | $181 |
| Merck | 10 | $144 |
| Novartis | 8 | $116 |
| Abbott | 6 | $110 |
| Almatica Pharma LLC | 7 | $101 |
| Eisai Inc. | 5 | $75 |
| Amgen(2 entities) | 5 | $75 |
| Idorsia Pharmaceuticals US Inc | 5 | $75 |
| Dexcom, Inc. | 3 | $73 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 4 | $73 |
| Azurity Pharmaceuticals, Inc. | 4 | $68 |
| Route 92 Medical, Inc. | 1 | $54 |
| Amarin Pharma, Inc. | 3 | $45 |
| Aerin Medical Inc. | 1 | $43 |
| Lundbeck LLC | 3 | $43 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $42 |
| Alkermes, Inc. | 2 | $38 |
| Daiichi Sankyo Inc. | 2 | $35 |
| Xeris Pharmaceuticals, Inc. | 2 | $26 |
| Medtronic | 1 | $24 |
| IBSA Pharma Inc. | 1 | $17 |
| Tanabe Pharma America, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| E.r. Squibb & Sons, L.L.C. | 1 | $13 |
How this compares
$6,635 in reported general payments places this provider in the 90th percentile of 2,084 family medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 98 | $106,985 |
| EliquisApixaban | 119 | $95,835 |
| JanuviaSitagliptin Phosphate | 66 | $89,535 |
| FarxigaDapagliflozin Propanediol | 89 | $79,492 |
| MounjaroTirzepatide | 42 | $55,817 |
| JardianceEmpagliflozin | 27 | $41,051 |
| JanumetSitagliptin Phos/Metformin Hcl | 21 | $30,950 |
| EntrestoSacubitril/Valsartan | 36 | $30,852 |
| TrulicityDulaglutide | 19 | $22,061 |
| LinzessLinaclotide | 20 | $20,234 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $14,440 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $13,127 |
| XareltoRivaroxaban | 19 | $11,813 |
| LivaloPitavastatin Calcium | 12 | $10,483 |
| Astagraf XlTacrolimus | 11 | $8,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet | $144 | $120,48587 claims |
| Novo NordiskOzempic | $1,120 | $106,98598 claims |
| PfizerEliquis, Paxlovid | $248 | $98,621134 claims |
| AstraZenecaFarxiga, Symbicort | $695 | $82,160101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $282 | $77,87961 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $268 | $48,35141 claims |
| AbbVieLinzess, Restasis, Synthroid, Combigan | $209 | $36,087105 claims |
| NovartisEntresto | $116 | $30,85236 claims |
| GSKAnoro Ellipta, Breo Ellipta | $197 | $12,66823 claims |
| Johnson & JohnsonXarelto | $297 | $11,81319 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $203 | $10,48312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,084 family medicine providers in New Jersey.
Other family medicine in Bridgewater
- Howard HassmanClementon$47.1M
- Matthew HongNorth Cape May$15.3M
- Rubaba HussainClark$3.8M
- Gaurang BrahmbhattHoboken$2.6M
- Michael DobrowClifton$2.1M
- Mikhail VarshavskiChatham$1.4M
- Amit BhalodiaCamden$707K
- Jennifer AmicoNew Brunswick$627K
- Janet ColeFar Hills$466K
- Matthew PintoMarlton$239K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.